Literature DB >> 2318815

Cap binding protein complex that restores protein synthesis in heat-shocked Ehrlich cell lysates contains highly phosphorylated eIF-4E.

B J Lamphear1, R Panniers.   

Abstract

Cell-free protein-synthesizing systems derived from Ehrlich ascites tumor cells that have been exposed to elevated temperatures retain the inhibition of translation that is seen at the cellular level. A multisubunit cap binding protein complex able to restore protein synthesis in these cell free systems was purified from Ehrlich ascites tumor cells via affinity chromatography using m7GTP-Sepharose and fast protein liquid chromatography on Mono Q. The purified complex contains an Mr 220,000 polypeptide (p220) and an Mr 28,000 polypeptide (p28), both of which are components of eukaryotic initiation factor 4F (eIF-4F). p28 is identical to eIF-4E. Restoring activity was relatively free of the Mr 46,000 polypeptide (p46) that is the third component of eIF-4F and does not appear to be dependent on its presence. p28 associated in a complex with p220 is 85% phosphorylated; however, the majority of p28 is not associated with p220, and this free form is only about 50% phosphorylated. The correlation between association of p28 with p220 and high levels of p28 phosphorylation suggests a possible role for phosphorylation in association of p220 with p28.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2318815

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  22 in total

1.  Phosphorylation of eIF4E attenuates its interaction with mRNA 5' cap analogs by electrostatic repulsion: intein-mediated protein ligation strategy to obtain phosphorylated protein.

Authors:  Joanna Zuberek; Aleksandra Wyslouch-Cieszynska; Anna Niedzwiecka; Michal Dadlez; Janusz Stepinski; Wojciech Augustyniak; Anne-Claude Gingras; Zhibo Zhang; Stephen K Burley; Nahum Sonenberg; Ryszard Stolarski; Edward Darzynkiewicz
Journal:  RNA       Date:  2003-01       Impact factor: 4.942

Review 2.  Mechanism and regulation of eukaryotic protein synthesis.

Authors:  W C Merrick
Journal:  Microbiol Rev       Date:  1992-06

3.  Eukaryotic translation initiation factor 4G is targeted for proteolytic cleavage by caspase 3 during inhibition of translation in apoptotic cells.

Authors:  W E Marissen; R E Lloyd
Journal:  Mol Cell Biol       Date:  1998-12       Impact factor: 4.272

4.  The mitogen-activated protein kinase signal-integrating kinase Mnk2 is a eukaryotic initiation factor 4E kinase with high levels of basal activity in mammalian cells.

Authors:  G C Scheper; N A Morrice; M Kleijn; C G Proud
Journal:  Mol Cell Biol       Date:  2001-02       Impact factor: 4.272

5.  Chaperone hsp27 inhibits translation during heat shock by binding eIF4G and facilitating dissociation of cap-initiation complexes.

Authors:  R Cuesta; G Laroia; R J Schneider
Journal:  Genes Dev       Date:  2000-06-15       Impact factor: 11.361

6.  Negative regulation of protein translation by mitogen-activated protein kinase-interacting kinases 1 and 2.

Authors:  U Knauf; C Tschopp; H Gram
Journal:  Mol Cell Biol       Date:  2001-08       Impact factor: 4.272

Review 7.  Translational regulation of the heat shock response.

Authors:  J M Sierra; J M Zapata
Journal:  Mol Biol Rep       Date:  1994-05       Impact factor: 2.316

8.  Efficient translation of an SSA1-derived heat-shock mRNA in yeast cells limited for cap-binding protein and eIF-4F.

Authors:  C A Barnes; M M MacKenzie; G C Johnston; R A Singer
Journal:  Mol Gen Genet       Date:  1995-03-10

9.  Expression of antisense RNA against initiation factor eIF-4E mRNA in HeLa cells results in lengthened cell division times, diminished translation rates, and reduced levels of both eIF-4E and the p220 component of eIF-4F.

Authors:  A De Benedetti; S Joshi-Barve; C Rinker-Schaeffer; R E Rhoads
Journal:  Mol Cell Biol       Date:  1991-11       Impact factor: 4.272

10.  Modification of eukaryotic initiation factor 4F during infection by influenza virus.

Authors:  D Feigenblum; R J Schneider
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.